MR-guided Tumour Boost

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · May 3, 2022

Keywords

ClinConnect Summary

This clinical trial, called MR-guided Tumour Boost, is exploring a new treatment approach for men with localized prostate cancer. The study aims to find out if giving a special type of radiation treatment, guided by MRI scans, can improve the outcome for patients with visible tumors in their prostate. The researchers are looking to recruit 40 men aged 18 and older who have been diagnosed with prostate cancer that is confined to the prostate and meets specific criteria based on risk levels.

To be eligible for the trial, participants should have localized prostate cancer that shows up on MRI and should not have had previous radiation therapy to the pelvic area. They must also be able to provide written consent to join the study. If you decide to participate, you will receive this MR-guided radiation treatment either before or after standard whole-gland radiation therapy, and you will be followed up by the medical team for up to 5 years to monitor your health and treatment effects. This study is currently recruiting, and it hopes to understand better how this new approach can help men with prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically-proven localized prostate cancer.
• • Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
• • Low-risk: cT1-T2a, PSA \<10, and Gleason score 6
• • Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
• • High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7
• • Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume
• • Planned for EBRT (+/- ADT)
• • ECOG 0 or 1
• • 18 years of age or older
• • Ability to provide written informed consent to participate in the study
• Exclusion Criteria:
• • Prior radiotherapy to pelvis
• • Radiological evidence of regional or distant metastases at the discretion of the treating physician.
• • Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
• • Ataxia Telangectasia and SLE
• • Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
• • Severe claustrophobia